Thrombosis and malignancy: Pathogenesis and prevention

In Vivo

Volumn 12, Issue 6, 1998, Pages 619-624

  Schwartz, Jonathan D ^a   Simantov, Ronit ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Malignancy; Pathogenesis; Prevention; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; CANCER PROCOAGULANT; CYCLOPHOSPHAMIDE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; PROCOAGULANT; TAMOXIFEN; THROMBOPLASTIN; VINCRISTINE; WARFARIN;

ANTICOAGULANT THERAPY; BREAST CANCER; CANCER; DRUG COST; GENETIC RISK; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; INTRAVENOUS CATHETER; MORBIDITY; PATHOGENESIS; REVIEW; THROMBOEMBOLISM; THROMBOSIS; THROMBOSIS PREVENTION;

EID: 0032410304     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Thomson AP: Thrombosis of the peripheral veins in visceral cancers: A tribute to Trousseau. Birmingham Med Rev 12: 259-264, 1937.
2. Billroth T: In Lectures on surgical pathology and therapeutics (transi from ed. 8). New Sydenham Society, 1878.
3. Wright TS. The pathogenesis and treatment of thrombosis. Circulation 5: 161, 1952.
4. Sproule EE: Carcinoma and venous thrombosis: The frequency of association of carcinoma in the body or tail of the pancrease with multiple venous thrombosis. Am J Cancer 34: 566-585, 1938.
5. Lieberman JS, Borrero J, Urdanetta E, Wright ES. Thrombophlebitis and cancer. JAMA 177: 542-545, 1961.
6. Sack GH, Levin J, Bell W: Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: Clinical, pathologic and therapeutic features. Medicine 56: 1-37, 1977.
7. Ambrus JL, Ambrus CM, Mink IB, Pickern JW: Causes of death in cancer patients. J Med 6: 61-64, 1975.
8. Ambrus JL, Ambrus CM, Pickern JW, Soldes S, Bross I: Hematologic changes and thromboembolic complications in neoplastic disease and their relationship to metastasis. J Med 6: 433-458, 1975.
9. Rickles FR, Edwards RL: Activation of blood coagulation in cancer: Trousseau's syndromerevisited. Blood 62: 14-31, 1983.
10. Pritchard KI, Paterson AHG, Paul NA et al: Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol 14: 2731-37, 1996.
11. Saphner T, Tormey DC, Gray R: Venous and arterial thrombosis in patients who received adjuvant chemotherapy for breast cancer. J Clin Oncol 9: 286-294, 1991.
12. Goudnough LT, Saito H, Manni A et al: Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-day chemotherapy regimen. A study of 159 patients. Cancer 54: 1264-68, 1984.
13. Scates SM: Diagnosis and treatment of cancer-related thrombosis. Sem Thromb Hem 18: 373-379, 1992.
14. Green KB, Silverstein RL. Hypercoagulability in cancer: Hematol Oncol Clin North A121 10: 499-530, 1996.
15. Piccioli A, Prandoni P, Ewenstein BM, Goldhaber SZ: Cancer and venous thromboembolism. Am Heart J 132: 850-855, 1996.
16. Morrison M. An analysis of the blood picture in 100 cases of malignancy. J Lab Clin Med 17: 1071, 1932.
17. Sun NC, McAfee WM, Hum GJ, Weiner JM: Hemostatic abnormalities in malignancy, a prospective study in one hundred eight patients. Part 1. Coagulation studies. Am J Clin Pathol 71: 10-16, 1979.
18. Carlsson S: Fibrinogen degradation products in serum from patients with cancer. Acta Chir Scand 139: 499-502, 1973.
19. Owens CA Jr., Bowie EJW: Chronic intravascular coagulation syndromes, a summary. Mayo Clin Proc 49: 673-679, 1974.
20. Yoda Y, Abe T: Fibrinopeptide A (FPA) level and fibrinogen kinetics in patients with malignant disease. Thromb Haemostas 46: 706-709, 1981.
21. Myers TJ, Rickles FR, Barb C, Cronlund M: Activation of blood coagulation in acute leukemia - Fibrinopeptide A (FPA) generation as an indicator of disease activity. Blood 57: 518-525, 1981.
22. Gordon SG: Cancer cell procoagulants and their implications. Hematol Oncol Clin North Am 6: 1359-74, 1992.
23. Nierodzik ML, Klepfish A, Karpatkin S: Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost 74: 282-290, 1995.
24. Dvorak HF, Quay SC, Orenstein NS et al: Tumor shedding and coagulation. Science 272: 924-925, 1981.
25. Dvorak HF, Van Dewater L, Bitzer M et al: Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res 43: 4434-42, 1983.
26. Kubota T, Andoh K, Sadakata H, Tanaka H, Kobayashi N: Tissue factor released form leukemic cells. Thromb Haemost 65: 59-63, 1991.
27. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbtlt S, Williamson RCN: Extrinsic pathway activation in cancer with high factor VIIa and tissue factor. Lancet 346: 1004-5, 1995.
28. Kakkar AK, Lemoine NR, Scully MF, Tebbutt S, Williamson RCN: Tissue factor expression correlates with histologie grade in human pancreatic carcinoma. Br J Surg 82: 1101-04, 1995.
29. Contrino G, Hair G, Kreutzer DL, Rickles FR: In situ detection of tissue factor in vascular endothelial: correlation with the malignant phenotype of human breast disease. Nature Med 2: 209-215, 1996.
30. Francis JL, Carvalho M, Francis DA: The clinical value of tissue factor assays. Blood Coag Fibrinol 6: Suppl. 1, S37-44, 1995.
31. Falanga A, Gordon SC: Isolation and characterization of cancer procoagulant: A cysteine protease from malignant tissue. Biochem 24: 5558-67, 1985.
32. Lawrence EA, Bowman DE, Moore DB, Bernstein GI. A thromboplastic property of neoplasms. Surg Forum 3: 694-698, 1952.
33. Gordon SG, Franks JJ, Lewis BJ: Cancer procoagulant: A factor X activating procoagulant from malignant tissue. Thromb Res 6: 127-137, 1975.
34. Donati MB, Gambacorti PC, Casali B et al: Cancer procoagulant activity in human tumor cells: Evidence from melanoma patients. Cancer Res 46: 6471-74, 1986.
35. Gordon SG: Cancer cell procoagulants and their implications. Hem/One Clin North Am 6: 1359-74, 1992.
36. Gordon SG, Benson B: An analysis of serum cancer procoagulant activity and its possible use as a tumor marker. Thromb Res 56: 431-440, 1989.
37. Rozwich DL, Kramer LC, Mielicki WP, Fotopoulos SS, Gordon SC: Applications of cancer procoagulant as an early detection tumor marker. Cancer 74: 1367-76, 1994.
38. Pineo GF, Rcgoeczi E, Hatton MWC, Brain MC: The activation of coagulation by extracts of mucous: A possible pathway of intravascular coagulation accompanying adenocarcinomas. J Lab Clin Med 82: 255-266, 1973.
39. Pineo GF, Brain MC, Gallus AS, Hirsh J, Hatton MWC, Regoeczi E: Tumors, mucus production and hypercoagulability. Ann NY Acad Sci 230: 262-70, 1974.
40. Gore I: Thrombosis and pancreatic cancer. Am J Path 29: 1093-1101, 1953.
41. Senger DR, Galli SJ, Dvorak AM, Peruzzi CA, Harvey VS, Dvorak HF: Tumor cells secret a vascular permeability factor that promotes accumulation of ascites fluid. Science 279: 983-985, 1983.
42. Senger DR, Peruzzi CA, Feder J, Dvorak HF: A.highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46: 5629-32, 1986.
43. Connolly D, Heuvelman D, Nelson R, Olander J, Eppley B, Delfino J et al: Tumor vascular permeability factor stimulates endothelial growth and angiogensis. J Clin Invest 84: 1470-78, 1989.
44. Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familetti PC et al: Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity and promotes monocyte migration. J Exp Med 1 72: 1535-45, 1990.
45. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA Jr: Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 160: 618-623, 1984.
46. Miyauchi S, Moroyama T, Kyoizumi S, Asakawa JI, Okamoto T, Takada K: Malignant tumor cell lines produce interleukin-1-like factor. In Vitro Cell Dev Biol 24: 753-758, 1988.
47. Bussolino F, Brevario F, Tetta C, Aglietta M, Mantovani A, Dejana E. Interleukin-1 stimulates platelet activating factor production in cultured human endothelial cells. J Clin Invest 77: 2027-33, 1986.
48. Dejana E, Brevario F, Erroi A, Bussolino L, Mussoni M, Grana M et al: Modulation of endothelial cell functions by different molecular species of interleukin-1. Blood 69: 695-701, 1987.
49. Lo SK, Cheung A, Zheng Q, Silverstein RL: Induction of tissue factor on monocytes by adhesion to endothelial cells. J Immunol 154: 768-77, 1995.
50. Noguchi M, Sakai T, Kisiel W: Induction of tissue factor on human endothelial cells by human tumor cell conditioned media. J Cell Biol (abstract) 707: 582a, 1988.
51. Identification and partial purification of a novel tumor-derived protein that induces tissue factor on cultured human endothelial cells. Biochem Biophys Res Corn 760: 222-7, 1989.
52. Bastida E, Ordinas A: Platelet contribution to metastatic foci: The role of cell- induced platelet activation. Haemostasis 18: 29-36: 1988.
53. Bastida E, Ordinas A, Jamieson GA: Differing platelet aggregating effects by two cell lines. Absence of role for platelet-derived ADP. Am J Hematol 77: 367-378, 1981.
54. Bastida E, Ordinas A, Jamieson GA: Idiosyncratic platelet responses to human tumor cells. Nature 297: 661-662, 1981.
55. Pearlstein EP, Ambrogio C, Gasic GJ, Karpatkin S: Inhibition of platelet aggregating activity of two human adenocarcinomas of the colon and an anaplasfic murine tumor with a specific thrombin inhibitor, dansyl argininc N-(3-ethyl-1, 5-pentanediyl) amide. Cancer Res 41: 4533-39, 1981.
56. Hara Y, Steiner M, Baldini MG: Characterization of the platelet-aggregating activity of tumor cells. Cancer Res 40: 1217-22, 1980.
57. Warren BA: The microinjury hypothesis and metastasis. In Hemostatic Mechanisms andMefastasis. KV Honn, BF Sloane eds. Nijhoff, Boston, 1984.
58. Esumi N, Fan D, Fidler IJ: Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res 57: 4549-56, 1991.
59. Pritchett TR, Lieskowsky G, Skinner DG: Extension of renal cell carcinoma into the vena cava: clnical review and surgical approach. J Urol 135: 460-464, 1986.
60. Hedderich GS, O'Connor RJ, Reid EC et al: Caval tumor thrombus complicating renal cell carcinoma: A surgical challenge. Surgery 702: 614-619, 1987.
61. Sharifi R, Ray P, Schade SG et al: Inferior vena cava thrombosis. Unusual presentation of testicular tumor. Urology 32:146-150, 1988.
62. Ritchy ML, Kinard R, Novick DE. Adrenal tumors: Involvement of the inferior vena cava. J Urol 138: 1134-36, 1987.
63. Nand S, Fisher SG, Salgia R, Fisher RI: Hemostatic abnormalities in untreated cancer: Incidence and correlation with thrombotic and hemorrhagic complications. J Clin Oncol 5: 1998-2003, 1987.
64. Honegger H, Anderson N, Hewitt LA, Tullis JL: Antithrombin III profiles in malignancy: Relationships to primary tumors and metastatic sites. Thromb Haemost 46: 500-503, 1981.
65. Rodeghiero F, Mannucci PM, Vigano PM, Barbui T, Gugliotta L, Cortellaro M et al: Liver dysfunction rather than intravascular coagulation is the main cause of low protein C and antithrombin III in acute leukemia. Blood 63: 965-69, 1984.
66. Uchimaya T, Matsumoto M, Kobayachi N. Studies on the pathogenesis of coagulopathy in patients with arterial thromboembolism and malignancy. Thromb Res 59: 955-965, 1990.
67. Troy K, Essex D, Rand J, Lema M, Cuttner J. Protein C and S levels in acute leukemia. Am J Hematol 37: 159-164, 1991.
68. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ et al. Rationale and experimental design for the VA cooperative study of anticoagulation (warfarin) in the treatment of cancer. Cancer 44: 732-741, 1979.
69. Zacharski LR, Donati MB, Rickles FR. Registry of clinical trials of antithrombotic drugs in cancer: second report. Thromb Haemost 70: 357-360, 1993.
70. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ et al: Effect of warfarin on survival in small cell carcinoma of the lung. JAMA 245: 831-835, 1981.
71. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ et al: Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Cancer 53: 2046-52, 1984.
72. Stanford CF: Anticoagulants in the treatment of small cell carcinoma of the bronchus. Thorax 34: 113-116, 1979.
73. Maurer LH, Herndon JE, Hollis DR, Aisner J, Carey RW, Skarin AT et al: Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: A cancer and leukemia group B study. J Clin Oncol 15: 3378-87, 1997.
74. Zacharski LR, Moritz TE, Baczek LA, Rickles FR, Edwards RL, Forman WB et al: Effect of mopidamol on survival in carcinoma of the lung and colon: Final report of veteran's administration cooperative study no. 188. J Natl Cancer Inst 80: 90-97, 1988.
75. Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C et al: Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 74: 38-45, 1994.
76. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG: Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 326: 975-982, 1992.
77. Prandoni P, Lensing AWA, Buller HR, Carta M, Cogo A, Vigo M et al: Comparison of subcutaneous low-molecular weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339: 441-445, 1992.
78. Green D, Hull RD, Brant R, Pineo G: Lower mortality in cancer patients treated with low-molecular weight versus standard heparin. Lancet 339: 1476, 1992.
79. Prandoni P: Antithrombotic strategies in patients with cancer. Thromb Haemost 78: 141-144, 1997.
80. Bona RD, Hickey AD, Wallace DM: Efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 78: 137-140, 1997.
81. Bona RD, Sivjee KY, Hickey AD, Wallace DM, Wajcs SB: The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 74: 1055-58, 1995.
82. Weiss RB, Tormey DC, Holland JF et al: Venous thrombosis during multimodal treatment of primary breast cancer. Cancer Treat Rep 65: 677-679, 1981.
83. Levine MN, Gent M, Hirsh J et al: The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 318: 404-407, 1988.
84. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A et al: Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage TV breast cancer. Lancet 343: 886-889, 1994.
85. Rajan R, Gafni A, Levine M, Hirsh J, Gent M: Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: An economic evaluation.
86. Eastridge BJ, Lefor AT: Complications of indwelling venous access devices in cancer patients. J Clin Oncol 13: 233, 1995.
87. Lokich JJ, Bothe A Jr, Bernotti P et al: Complications and management of-implanted venous access catheters. J Clin Oncol 3: 710, 1985.
88. Peul V, Caudry M, Le Metayer P et al: Superior vena cava thrombosis related to catheter malposition in cancer chemotherapy given through implanted ports. Cancer 72: 2248, 1993.
89. Bern MM, Bothe A Jr, Bistrian B, Champagne CD, Keane MS, Blackburn GL: Prophylaxis against central vein thrombosis with low-dose warfarin. Surgery 99: 216-220, 1986.
90. Bern MM, Lokich JJ, Wallach SR, Bothe A Jr, Benotti PN, Arkin CF et al: Very low doses of warfarin can prevent thrombosis in central venous catheters: A randomized prospective trial. Ann Intern Med 112: 423-428, 1990.
91. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, A6ad A. Upper extremity deep venous thrombosis in cancer patients with venous access devices - prophylaxis with a low molecular weight heparin (fragmin). Thromb Haemost 75: 251-3, 1996.
92. Gallus AS: Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thromb Haemost 78: 126-132, 1997.
93. Clagett PG, Reisch JS: Prevention of venous thromboembolism in general surgical patients. Results of a meta-analysis. Ann Surg 205: 227-240, 1988.
94. Koppenhagen K, Adolf J, Matthes M, Troster E, Roder JD, Haas S et al: Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery. Thromb Haemost 67: 627-630, 1992.
95. Gallus A, Cade J, Ockelford P, Hepburn S, Maas M, Magnani H et al: Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised multicentre comparison. Thromb Haemost 70: 562-567, 1993.
96. Nurmohamed MT, Verhaeghe R, Haas S, Iriarte JA, Vogel G, van Rij AM et al: A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Amer J Surg 169: 567-571, 1995.
97. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallbook T, Hedberg M. Br J Surg 82: 496-501, 1995.
98. Clarke-Pearson DL, Synan IS, Creasman WT: Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy. Am J Obstet Gynecol 147: 369-375, 1983.
99. Clarke-Pearson DL, DeLong E, Synan IS, Soper JT, Creasman WT, Coleman RE. A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstet Gynecol 75: 684-689, 1990.
100. Clarke-Pearson DL, Synan IS, Dodge R, Soper JT, Berchuck A, Coleman RE: A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol 765: 1146-54, 1993.
101. Turpie AGG, Gallus AS Beattie WS, Hirsh J: Prevention of venous thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf. Neurology 27: 435-438, 1977.
102. Nurmohamed MT, van Riel AM, Henkens CMA, Koopman MMW, Que GTH, d'Azemar P et al: Low molecular weight heparin and compression stockings in the prevention of venous thrombosis in neurosurgery. Thromb Haemost 75: 223-228, 1996.
103. Ruff RL, Posner JB: Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol 73: 334-336, 1983.
104. Dhami MS, Bona RD, Calogero JA, Hellman RM: Venous thromboembolism and high-grade gliomas. Thromb Haemost 70: 393-396, 1993.
105. Quevedo JF, Buckner JC, Schmidt JL, Dinapoli RP, O'Fallon JR: Thromboembolism in patients with high-grade glioma. Mayo Clin Proc 69: 329-332, 1994.
106. Choucair AK, Silver P, Levin VA: Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. J Neurosurg 66: 357-358, 1987.
107. Olin JW, Young JR, Graor RA, Ruschhaupt WF, Beven EG, Bay JW: Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors: Anticoagulants or inferior vena cava filter? Arch Intern Med 147: 2177-79, 1987.
108. Poort SR, Rosendaal FR, Reitsma PH and Bertina RM: A common genetic varaition in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood, 88: 3698-3703,